Industry News — Clinical Updates

VIBRANT Study Yields Positive Results for Eylea in Treating Macular Edema Following BRVO

October 21, 2013 – Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) announced positive top-line results for Eylea (aflibercept) from the phase 3 VIBRANT trial in treating macular edema following branch retinal vein occlusion (BRVO). 

VIBRANT was a double-masked, randomized, active-controlled study of 183 patients with macular edema following BRVO. In the trial, 53% of patients who received aflibercept 2 mg every 4 weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study. This compares with 27% of patients in the laser group (P < .001) who had the same gain.

In addition, patients who received aflibercept 2 mg every 4 weeks achieved a 17.0-letter mean improvement over baseline in best-corrected visual acuity (BCVA) compared with a 6.9-letter mean improvement in patients who received laser (P < .0001), a key secondary endpoint.

The incidence of serious adverse events (SAE) was 9.9% in the aflibercept group and 9.8% in the laser group. One death and 1 Anti-Platelet Trialists' Collaboration (APTC)-defined event (non-fatal stroke) occurred in the laser group. The most common ocular adverse events in the aflibercept group were conjunctival hemorrhage and eye pain; there were no cases of intraocular inflammation. There was one ocular SAE (traumatic cataract) in the aflibercept group. 

VIBRANT is the first phase 3 trial for this indication in which an anti-VEGF agent was directly compared with an active comparator and is the eighth positive trial from the aflibercept phase 3 program.

Regeneron intends to submit a US regulatory application within the next several months to gain marketing approval for aflibercept in the treatment of macular edema following BRVO.

Posted October 21, 2013

Designed and built in Chicago by Webitects